Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 LY2606368 monotherapy in extensive-stage small cell lung cancer
NL-OMON43518Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of prexasertib in small cell lung cancer (SCLC), sponsored by Eli Lilly and Company. Primary endpoint: Overall response rate. Started Oct 2016; status: active, not recruiting.
02
Drugs
prexasertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON43518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43518.